Trevi Therapeutics, Inc. — fact timeline

Trevi Therapeutics, Inc.: Increased authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2026-06-03).

“At the Annual Meeting, the Company’s stockholders approved an amendment (the “Amendment”) to the Company’s restated certificate of incorporation (“Certificate of Incorporation”) to increase the number of authorized shares of the Company’s common stock from 200,000,0000 shares to 400,000,000 shares. The Amendment became effective upon the Company’s filing of a Certificate of Amendment to the Restated Certificate of Incorporation with the Secretary of State of the State of Delaware on June 3, 2026”

Trevi Therapeutics, Inc. shareholders approved Amendment to increase authorized shares of common stock from 200,000,000 to 400,000,000 at the 2026-06-03 meeting.

“The Amendment to increase the number of authorized shares of common stock from 200,000,000 shares to 400,000,000 shares was approved. For: 110,453,620 Against: 3,872,599 Abstain: 17,676”

Trevi Therapeutics, Inc. shareholders approved Approval of A&R 2019 Plan at the 2026-06-03 meeting.

“The A&R 2019 Plan was approved. For: 98,140,470 Against: 1,961,030 Abstain: 101,991 Broker Non-Votes: 14,140,404”

Trevi Therapeutics, Inc. shareholders approved Advisory approval of compensation of named executive officers at the 2026-06-03 meeting.

“The compensation of the Company's named executive officers was approved, on an advisory basis. For: 98,119,461 Against: 1,982,126 Abstain: 101,904 Broker Non-Votes: 14,140,404”

Trevi Therapeutics, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-03 meeting.

“The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified. For: 114,001,970 Against: 223,323 Abstain: 118,602”

Trevi Therapeutics, Inc. shareholders approved Election of Michael Heffernan as Class I director at the 2026-06-03 meeting.

“Michael Heffernan was elected to the Board as a Class I director for a term expiring at the 2029 annual meeting of stockholders. For: 81,567,765 Withheld: 18,635,726 Broker Non-Votes: 14,140,404”

Trevi Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income Net loss: For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.

“For the first quarter of 2026, the Company reported a net loss of $13.2 million, compared to a net loss of $10.3 million in the same period in 2025.”

Trevi Therapeutics, Inc. entered into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters valued at $13.00 per share (effective 2026-04-16).

“On April 16, 2026, Trevi Therapeutics, Inc., a Delaware corporation (the “Company”), entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC and Leerink Partners LLC, as representatives of the several underwriters (the “Underwriters”), relating to an underwritten offering (the “Offering”) of 11,600,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”).”

David Clark departed as Chief Medical Officer at Trevi Therapeutics, Inc..

“David Clark, MBChB, MRCP, had stepped down as the Company’s Chief Medical Officer, effective as of September 27, 2024.”

James Cassella resigned as Member of the Board of Directors at Trevi Therapeutics, Inc..

“Dr. Cassella resigned from his position as a member of the Board of Directors of the Company, effective as of September 30, 2024.”

James Cassella was appointed as Chief Development Officer at Trevi Therapeutics, Inc..

“announced that James Cassella, Ph.D., had agreed to join the Company as its Chief Development Officer.”

Trevi Therapeutics, Inc. reported quarter ended March 31, 2024 results: net income Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.. Guidance reaffirmed.

“Net loss: For the first quarter of 2024, the Company reported a net loss of $10.9 million, compared to a net loss of $6.4 million in the same period in 2023.”

Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: net income Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.. Guidance reaffirmed.

“Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.”